Compare CNK & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNK | ABCL |
|---|---|---|
| Founded | 1984 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.1B |
| IPO Year | 2007 | 2020 |
| Metric | CNK | ABCL |
|---|---|---|
| Price | $40.02 | $11.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 13 |
| Target Price | ★ $42.09 | $17.17 |
| AVG Volume (30 Days) | 1.8M | ★ 3.8M |
| Earning Date | 11-03-2026 | 11-09-2026 |
| Dividend Yield | ★ 0.89% | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,115,000,000.00 | $75,128,000.00 |
| Revenue This Year | $18.24 | N/A |
| Revenue Next Year | $1.07 | $7.12 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 2.15 | ★ 160.56 |
| 52 Week Low | $21.60 | $2.75 |
| 52 Week High | $40.75 | $14.98 |
| Indicator | CNK | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 62.09 | 49.85 |
| Support Level | $34.40 | $11.78 |
| Resistance Level | $40.53 | $12.88 |
| Average True Range (ATR) | 1.42 | 0.90 |
| MACD | -0.05 | -0.06 |
| Stochastic Oscillator | 91.40 | 43.72 |
Cinemark Holdings Inc is a geographically diverse operator in the motion picture exhibition industry in the United States. The company generates revenue from filmed entertainment box office receipts and concession sales, with additional revenue from screen advertising, screen rentals, and other revenue streams, such as transactional fees, vendor marketing promotions, studio trailer placements, meeting rentals, and electronic video games located in some of the theatres. Cinemark manages its business under two reportable segments: U.S. markets and international markets. The majority of its revenue is generated from the U.S. markets segment.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.